C Dirk Keene

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Biomarkers for Alzheimer's disease
    Joshua A Sonnen
    Department of Pathology, University of Washington, Seattle, WA 98104 2499, USA
    Expert Rev Neurother 7:1021-8. 2007
  2. pmc A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions
    C Dirk Keene
    Department of Pathology, Harborview Medical Center, University of Washington Medical Center, Seattle, 98104, USA
    Acta Neuropathol 117:329-38. 2009
  3. pmc Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow
    C Dirk Keene
    Harborview Medical Center, Box 359645, 325 Ninth Ave, Seattle, WA 98104, USA
    Am J Pathol 177:346-54. 2010
  4. pmc APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease
    Yue Yang
    Department of Pathology, University of Washington, Seattle, Washington, USA
    Am J Pathol 183:905-17. 2013
  5. pmc Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation
    Yue Yang
    Department of Pathology, University of Washington, Seattle, WA, USA
    Exp Mol Pathol 95:7-17. 2013
  6. pmc Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease
    C Dirk Keene
    Department of Pathology, University of Washington, Seattle, WA, United States
    Curr Opin Neurobiol 21:920-8. 2011
  7. pmc Protection of hippocampal neurogenesis from toll-like receptor 4-dependent innate immune activation by ablation of prostaglandin E2 receptor subtype EP1 or EP2
    C Dirk Keene
    Department of Pathology, University of Washington, Box 359791, Seattle, WA 98104, USA
    Am J Pathol 174:2300-9. 2009
  8. pmc Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid β neurotoxicity in vitro
    Xianwu Li
    Department of Pathology, University of Washington, Box 359645, Seattle, WA 98104, USA
    J Neuroimmune Pharmacol 8:87-93. 2013
  9. pmc Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease
    Patrick J Cimino
    Department of Pathology, University of Washington, Seattle, WA 63110 1093, USA
    Exp Mol Pathol 94:366-71. 2013
  10. pmc Therapeutic implications of the prostaglandin pathway in Alzheimer's disease
    Eiron Cudaback
    University of Washington Harborview Medical Center, Department of Pathology, Box 359791, 325 Ninth Ave, Seattle, WA 98104, USA
    Biochem Pharmacol 88:565-72. 2014

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Biomarkers for Alzheimer's disease
    Joshua A Sonnen
    Department of Pathology, University of Washington, Seattle, WA 98104 2499, USA
    Expert Rev Neurother 7:1021-8. 2007
    ..The next 5 years will see standardization of more established approaches, and the combination of different modalities into the most effective means for assessing different stages of AD...
  2. pmc A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions
    C Dirk Keene
    Department of Pathology, Harborview Medical Center, University of Washington Medical Center, Seattle, 98104, USA
    Acta Neuropathol 117:329-38. 2009
    ..This report, for the first time, highlights the potential for graft overgrowth in a patient receiving fetal neural transplantation...
  3. pmc Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow
    C Dirk Keene
    Harborview Medical Center, Box 359645, 325 Ninth Ave, Seattle, WA 98104, USA
    Am J Pathol 177:346-54. 2010
    ..Our results provide a foundation for an adult stem cell-based therapy to suppress soluble Abeta peptide and plaque accumulation in the cerebrum of patients with AD...
  4. pmc APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease
    Yue Yang
    Department of Pathology, University of Washington, Seattle, Washington, USA
    Am J Pathol 183:905-17. 2013
    ..Together, these findings suggest that BMT-derived APOE3-expressing cells are superior to those that express APOE4 in their ability to mitigate the behavioral and neuropathological changes in experimental Alzheimer disease. ..
  5. pmc Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation
    Yue Yang
    Department of Pathology, University of Washington, Seattle, WA, USA
    Exp Mol Pathol 95:7-17. 2013
    ..Advancing the therapeutic applications of BMT to neurodegenerative diseases will require identification of the barrier mechanisms that MyA, but not NMyA, BMT is able to overcome...
  6. pmc Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease
    C Dirk Keene
    Department of Pathology, University of Washington, Seattle, WA, United States
    Curr Opin Neurobiol 21:920-8. 2011
    ....
  7. pmc Protection of hippocampal neurogenesis from toll-like receptor 4-dependent innate immune activation by ablation of prostaglandin E2 receptor subtype EP1 or EP2
    C Dirk Keene
    Department of Pathology, University of Washington, Box 359791, Seattle, WA 98104, USA
    Am J Pathol 174:2300-9. 2009
    ....
  8. pmc Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid β neurotoxicity in vitro
    Xianwu Li
    Department of Pathology, University of Washington, Box 359645, Seattle, WA 98104, USA
    J Neuroimmune Pharmacol 8:87-93. 2013
    ..Based on these data, we conclude that suppressing neuronal EP1 signaling may represent a promising therapeutic approach to ameliorate Aβ peptide neurotoxicity...
  9. pmc Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease
    Patrick J Cimino
    Department of Pathology, University of Washington, Seattle, WA 63110 1093, USA
    Exp Mol Pathol 94:366-71. 2013
    ..In combination with earlier cell culture results, our in vivo results presented here suggest DOCK2 contributes to Aβ plaque burden via regulation of microglial innate immune function and may represent a novel therapeutic target for AD...
  10. pmc Therapeutic implications of the prostaglandin pathway in Alzheimer's disease
    Eiron Cudaback
    University of Washington Harborview Medical Center, Department of Pathology, Box 359791, 325 Ninth Ave, Seattle, WA 98104, USA
    Biochem Pharmacol 88:565-72. 2014
    ..Directed strategies such as these may ultimately help to delay the deleterious consequences of brain aging and might someday lead to new therapies for AD and other chronic neurodegenerative diseases. ..
  11. pmc Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults
    Nadia Postupna
    Department of Pathology, University of Washington, Seattle, USA
    Brain Pathol 22:472-84. 2012
    ....
  12. pmc Eicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor
    Xianwu Li
    Department of Pathology, University of Washington, Box 359645, Seattle, WA 98104, USA
    FASEB J 26:3075-83. 2012
    ....
  13. pmc Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment
    Luis F Gonzalez-Cuyar
    Department of Pathology, University of Washington, Seattle, USA
    Curr Neurol Neurosci Rep 11:455-63. 2011
    ..Future applications will likely focus on diagnosis of latent or early-stage disease, assessment of disease progression, mechanism of injury, and response to experimental therapeutics...
  14. pmc Apolipoprotein E isoform-dependent microglia migration
    Eiron Cudaback
    Department of Pathology, Neuropathology Division, University of Washington, Seattle, Washington, USA
    FASEB J 25:2082-91. 2011
    ..This study, for the first time, demonstrates apoE dependence and apoE isoform-specific modulation of microglial migration in response to distinct chemotactic stimuli commonly associated with neurodegenerative disease...
  15. pmc Suppressed microglial E prostanoid receptor 1 signaling selectively reduces tumor necrosis factor alpha and interleukin 6 secretion from toll-like receptor 3 activation
    Xianwu Li
    Department of Pathology, University of Washington, Seattle, Washington, USA
    Glia 59:569-76. 2011
    ..In combination with the ability of EP1 suppression to ameliorate excitotoxicity, these data point to blockade of EP1 as an attractive candidate therapeutic for neurodegenerative diseases...
  16. pmc Therapeutic targets in prostaglandin E2 signaling for neurologic disease
    P J Cimino
    Division of Neuropathology, University of Washington School of Medicine, Box 359791, Harborview Medical Center, Seattle, WA 98104, USA
    Curr Med Chem 15:1863-9. 2008
    ..However promising these preclinical studies are, they have yet to be followed by clinical trials targeting any EP receptor in neurologic diseases...
  17. pmc Proteomics of human neurodegenerative diseases
    Jing Zhang
    Department of Pathology, University of Washington, Harborview Medical Centre, Seattle, Washington 98104, USA
    J Neuropathol Exp Neurol 67:923-32. 2008
    ..Here, we review the fundamentals of commonly used proteomic approaches and the outcomes of these investigations with autopsy and cerebrospinal fluid samples from patients with neurodegenerative diseases...
  18. pmc Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models
    Eric A Horne
    Department of Pharmacology, University of Washington, 1959 N E Pacific St, Seattle, WA 98195 7280, USA
    Eur J Neurosci 37:429-40. 2013
    ..Loss of CB(1) signaling in NPY/nNOS-expressing interneurons could contribute to the impairment of basal ganglia functions linked to HD...
  19. pmc Suppressed retinal degeneration in aged wild type and APPswe/PS1ΔE9 mice by bone marrow transplantation
    Yue Yang
    Department of Pathology, University of Washington, Seattle, Washington, USA
    PLoS ONE 8:e64246. 2013
    ..Thus, BMT is neuroprotective in age-related as well as AD-related retinal degeneration, and may be a result of alterations in innate immune function and oxidative stress in BMT recipient mice...
  20. ncbi request reprint Parahippocampal corpora amylacea: case report
    Taylor J Abel
    Department of Neurological Surgery, University of Washington, Seattle, Washington 98195, USA
    Neurosurgery 66:E1206-7. 2010
    ..Reports of massive localized accumulation of CA in the brain outside of these conditions are rare...
  21. doi request reprint Massive intractable hemoptysis due to idiopathic granulomatous pulmonary veno-occlusive disease
    T Eoin West
    Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98104, USA
    Respir Care 58:e56-9. 2013
    ....
  22. pmc Epigenetic signature and enhancer activity of the human APOE gene
    Chang En Yu
    Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, WA 98108, USA
    Hum Mol Genet 22:5036-47. 2013
    ....